14.46
price up icon0.49%   0.07
pre-market  Pre-market:  14.40   -0.06   -0.41%
loading
Biohaven Ltd stock is traded at $14.46, with a volume of 2.79M. It is up +0.49% in the last 24 hours and down -11.02% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$14.39
Open:
$14.48
24h Volume:
2.79M
Relative Volume:
1.39
Market Cap:
$1.71B
Revenue:
-
Net Income/Loss:
$-804.34M
P/E Ratio:
-1.5367
EPS:
-9.41
Net Cash Flow:
$-531.06M
1W Performance:
-6.47%
1M Performance:
-11.02%
6M Performance:
-60.12%
1Y Performance:
-56.76%
1-Day Range:
Value
$13.87
$14.62
1-Week Range:
Value
$13.87
$15.65
52-Week Range:
Value
$13.87
$55.70

Biohaven Ltd Stock (BHVN) Company Profile

Name
Name
Biohaven Ltd
Name
Phone
203-404-0410
Name
Address
215 CHURCH STREET, NEW HAVEN, CT
Name
Employee
256
Name
Twitter
@biohavenpharma
Name
Next Earnings Date
2022-11-07T13:30:00.000Z
Name
Latest SEC Filings
Name
BHVN's Discussions on Twitter

Compare BHVN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BHVN
Biohaven Ltd
14.46 1.71B 0 -804.34M -531.06M -9.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-19-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-11-25 Initiated Deutsche Bank Buy
Sep-16-24 Initiated Jefferies Buy
Sep-04-24 Initiated Bernstein Outperform
Jul-24-24 Initiated Morgan Stanley Overweight
Feb-16-24 Initiated RBC Capital Mkts Outperform
Feb-06-24 Initiated UBS Buy
Dec-22-23 Initiated H.C. Wainwright Buy
Dec-08-23 Initiated Robert W. Baird Outperform
Jan-24-23 Initiated SVB Securities Outperform
Jan-04-23 Initiated JP Morgan Overweight
Dec-02-22 Initiated BTIG Research Buy
Oct-26-22 Upgrade Cantor Fitzgerald Neutral → Overweight
Oct-12-22 Initiated Piper Sandler Overweight
Aug-19-22 Downgrade Piper Sandler Overweight → Neutral
Aug-08-22 Downgrade Wedbush Outperform → Neutral
May-11-22 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-19-21 Resumed Morgan Stanley Equal-Weight
Aug-10-21 Downgrade UBS Buy → Neutral
Aug-03-21 Reiterated Canaccord Genuity Buy
Mar-11-21 Initiated UBS Buy
Dec-15-20 Initiated H.C. Wainwright Buy
Apr-17-20 Initiated Cowen Outperform
Feb-10-20 Downgrade Oppenheimer Outperform → Perform
Feb-06-20 Initiated Mizuho Buy
Nov-22-19 Initiated Wedbush Outperform
Jun-25-19 Reiterated Canaccord Genuity Buy
May-06-19 Initiated Goldman Buy
Apr-09-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19 Reiterated Needham Buy
Jul-03-18 Reiterated Needham Buy
Jul-02-18 Reiterated Needham Buy
Apr-05-18 Downgrade Barclays Overweight → Equal Weight
Feb-22-18 Reiterated Canaccord Genuity Buy
Dec-15-17 Initiated Canaccord Genuity Buy
Oct-03-17 Reiterated Needham Buy
View All

Biohaven Ltd Stock (BHVN) Latest News

pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Biohaven stock hits 52-week low at 14.32 USD By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 18, 2025

Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN S - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biohaven price target lowered to $55 from $68 at JPMorgan - TipRanks

Jun 18, 2025
pulisher
Jun 15, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ... - Bluefield Daily Telegraph

Jun 15, 2025
pulisher
Jun 12, 2025

Biohaven Insiders Added US$6.28m Of Stock To Their Holdings - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Investigation Underway: Biohaven Ltd. (BHVN)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

New Haven-based bioscience firms Bexorg, Biohaven agree to collaborate - Hartford Business Journal

Jun 11, 2025
pulisher
Jun 11, 2025

BHVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Biohaven Ltd. - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 10, 2025

Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research C - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Kalkine : Biohaven Ltd Shift Amid Sector Moves and Earnings Per Share Focus - Kalkine Media

Jun 10, 2025
pulisher
Jun 10, 2025

Biohaven, Bexorg Collaborate to Develop CNS Therapies - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - The Manila Times

Jun 10, 2025
pulisher
Jun 10, 2025

Bexorg announces multi-program research collaboration with Biohaven - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Bexorg Announces Research Collaboration with Biohaven - GlobeNewswire

Jun 10, 2025
pulisher
Jun 10, 2025

Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Parallel Advisors LLC - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Levi & Korsinsky Investigates Possible Securities Fraud by Biohaven Ltd. (BHVN) - ACCESS Newswire

Jun 09, 2025
pulisher
Jun 07, 2025

Fraud Investigation: Levi & Korsinsky Investigates Biohaven Ltd. (BHVN) on Behalf of Shareholders - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 06, 2025

Levi & Korsinsky Investigating Whether Biohaven Ltd. (BHVN) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.

Jun 06, 2025
pulisher
Jun 05, 2025

Ongoing Biohaven Ltd. (BHVN) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 04, 2025

Biohaven Ltd. Highlights Strategic Focus in Investor Presentation - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Biohaven Ltd. (BHVN) - ACCESS Newswire

Jun 04, 2025
pulisher
Jun 04, 2025

Sector Update: Health Care - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates - marketscreener.com

Jun 04, 2025
pulisher
Jun 03, 2025

Shareholders Alert: Investigation Into Biohaven Ltd. (BHVN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 01, 2025

Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks

Jun 01, 2025
pulisher
Jun 01, 2025

Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey

Jun 01, 2025
pulisher
May 31, 2025

Jim Cramer’s Thoughts on These 10 Stocks - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize

May 31, 2025
pulisher
May 31, 2025

How To Trade (BHVN) - news.stocktradersdaily.com

May 31, 2025
pulisher
May 31, 2025

Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks

May 31, 2025
pulisher
May 31, 2025

Biohaven stock hits 52-week low at $14.36 amid market challenges By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Morgan Stanley maintains Biohaven stock with $63 target - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law Violations - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks

May 30, 2025
pulisher
May 29, 2025

Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 29, 2025

Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - MarketScreener

May 29, 2025
pulisher
May 29, 2025

Cowen reiterates Buy on Biohaven stock, maintains $75 target - Investing.com

May 29, 2025
pulisher
May 29, 2025

Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks

May 29, 2025
pulisher
May 29, 2025

Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider

May 29, 2025

Biohaven Ltd Stock (BHVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Biohaven Ltd Stock (BHVN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Car Bruce
Chief Scientific Officer
Jan 05 '25
Option Exercise
0.00
4,750
0
7,133
Gentile Kimberly
SVP, Clinical Operations
Jan 05 '25
Option Exercise
0.00
3,750
0
99,719
Clark George C.
VP, Chief Accounting Officer
Jan 05 '25
Option Exercise
0.00
2,500
0
66,168
Buten Matthew
Chief Financial Officer
Jan 05 '25
Option Exercise
0.00
4,250
0
196,013
Coric Vlad
Chief Executive Officer
Jan 05 '25
Option Exercise
0.00
14,250
0
1,803,409
CHILDS JOHN W
Director
Dec 30 '24
Buy
35.94
29,000
1,042,393
2,368,741
CHILDS JOHN W
Director
Oct 02 '24
Buy
47.50
21,052
999,970
21,052
Coric Vlad
Chief Executive Officer
Oct 02 '24
Buy
47.50
21,052
999,970
861,942
Bailey Gregory
Director
Sep 24 '24
Buy
44.19
5,000
220,966
1,620,071
CHILDS JOHN W
Director
Jul 18 '24
Buy
35.67
28,400
1,012,983
2,339,741
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Cap:     |  Volume (24h):